Skip to main content
NCBI home page
Gut logoLink to Gut
. 1977 Jul;18(7):547–555. doi: 10.1136/gut.18.7.547

Behaviour of 125I-fibrinogen and 131I-albumin in experimental galactosamine-induced hepatitis.

I Mahn, H Merkel, E L Sattler, G Müller-Berghaus
PMCID: PMC1411567  PMID: 873336

Abstract

The turnover of 125I-labelled fibrinogen and 131I-labelled albumin was studied in the course of galactosamine-induced hepatitis in rabbits. In addition to galactosamine, some animals were treated with epsilon-aminocaproic acid (EACA) to inhibit the activation of the fibrinolytic system. The infusion of galactosamine and EACA caused generation of fibrin-rich microclots in the renal glomerular capillaries in seven out of 12 rabbits. Correspondingly, the incorporation of 125I-radioactivity into liver, spleen, and kidneys was pronounced in galactosamine- and EACA-treated rabbits compared with control animals treated with EACA. An acceleration of the 125I-fibrinogen elimination from the plasma was observed between eight and 12 hours after the start of the galactosamine infusion. The administration of heparin in addition to galactosamine and EACA prevented the occurrence of intravascular coagulation, but shortened the survival times of the animals because of bleeding into visceral organs. The elimination of 131I-albumin in plasma as well as the distribution of 131I-radioactivity in organs were similar in all the rabbits independent of the treatment with galactosamine, EACA, or heparin. The experiments indicate that, in addition to diminished synthesis of coagulation factors, disseminated intravascular coagulation is involved in galactosamine-induced hepatitis and contributes to the haemostatic disorder.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom A. L. Intravascular coagulation and the liver. Br J Haematol. 1975 May;30(1):1–7. doi: 10.1111/j.1365-2141.1975.tb00511.x. [DOI] [PubMed] [Google Scholar]
  2. Gallus A. S., Lucas C. R., Hirsh J. Coagulation studies in patients with acute infectious hepatitis. Br J Haematol. 1972 Jun;22(6):761–771. doi: 10.1111/j.1365-2141.1972.tb05720.x. [DOI] [PubMed] [Google Scholar]
  3. Hillenbrand P., Parbhoo S. P., Jedrychowski A., Sherlock S. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure. Gut. 1974 Feb;15(2):83–88. doi: 10.1136/gut.15.2.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Keppler D., Lesch R., Reutter W., Decker K. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol. 1968 Oct;9(2):279–290. doi: 10.1016/0014-4800(68)90042-7. [DOI] [PubMed] [Google Scholar]
  5. Lasch H. G., Heene D. L., Huth K., Sandritter W. Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy ("Verbrauchskoagulopathie"). Am J Cardiol. 1967 Sep;20(3):381–391. doi: 10.1016/0002-9149(67)90062-8. [DOI] [PubMed] [Google Scholar]
  6. Mahn I., Müller-Berghaus G. Studies on catabolism of 125I-labelled fibrinogen in normal rabbits and in rabbits with indwelling intravenous catheters: methodologic aspects. Haemostasis. 1975;4(1):41–50. [PubMed] [Google Scholar]
  7. McFARLANE A. S. Efficient trace-labelling of proteins with iodine. Nature. 1958 Jul 5;182(4627):53–53. doi: 10.1038/182053a0. [DOI] [PubMed] [Google Scholar]
  8. McFarlane A. S. IN VIVO BEHAVIOR OF I-FIBRINOGEN. J Clin Invest. 1963 Mar;42(3):346–361. doi: 10.1172/JCI104721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Müller-Berghaus G., Reuter C., Bleyl U. Experimental galactosamine-induced hepatitis. Effect of anticoagulant and antifibrinolytic agents on microclot formation. Am J Pathol. 1976 Feb;82(2):393–406. [PMC free article] [PubMed] [Google Scholar]
  10. PROCTOR R. R., RAPAPORT S. I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961 Sep;36:212–219. doi: 10.1093/ajcp/36.3.212. [DOI] [PubMed] [Google Scholar]
  11. Rake M. O., Flute P. T., Pannell G., Shilkin K. B., Williams R. Experimental hepatic necrosis: studies on coagulation abnormalities, plasma clearance, and organ distribution of 125I-labelled fibrinogen. Gut. 1973 Jul;14(7):574–580. doi: 10.1136/gut.14.7.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rake M. O., Flute P. T., Pannell G., Williams R. Intravascular coagulation in acute hepatic necrosis. Lancet. 1970 Mar 14;1(7646):533–537. doi: 10.1016/s0140-6736(70)90767-1. [DOI] [PubMed] [Google Scholar]
  13. Regoeczi E. Iodine-labelled fibrinogen: a review. Br J Haematol. 1971 Jun;20(6):649–663. doi: 10.1111/j.1365-2141.1971.tb00804.x. [DOI] [PubMed] [Google Scholar]
  14. Reutter W., Lesch R., Keppler D., Decker K. Galactosamin-Hepatitis. Naturwissenschaften. 1968 Oct;55(10):497–497. doi: 10.1007/BF00599726. [DOI] [PubMed] [Google Scholar]
  15. SCHULTZE H. E., SCHWICK G. Die klinische Bedeutung der differenzierten Bestimmung von Prothrombin und Acceleratoren der Blutgerinnung. I. Medizinische. 1953 Oct 17;42:1354–1357. [PubMed] [Google Scholar]
  16. Tytgat G. N., Collen D., Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. South Med J. 1971 Oct;64(10):1690–1701. [PubMed] [Google Scholar]
  17. VERSTRAETE M., VERMYLEN C., VERMYLEN J., VANDENBROUCKE J. EXCESSIVE CONSUMPTION OF BLOOD COAGULATION COMPONENTS AS CAUSE OF HEMORRHAGIC DIATHESIS. Am J Med. 1965 Jun;38:899–908. doi: 10.1016/0002-9343(65)90009-4. [DOI] [PubMed] [Google Scholar]
  18. Verstraete M., Vermylen J., Collen D. Intravascular coagulation in liver disease. Annu Rev Med. 1974;25:447–455. doi: 10.1146/annurev.me.25.020174.002311. [DOI] [PubMed] [Google Scholar]
  19. WROBLEWSKI F., LADUE J. S. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med. 1956 Apr;91(4):569–571. doi: 10.3181/00379727-91-22330. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES